CDMO Quote, Financials, Valuation and Earnings

Catalent has a net margin of -51.99% compared to Avid Bioservices's net margin of -12.61%. Avid Bioservices's return on equity of -143.94% beat Catalent's return on equity of -11.29%.

Avid Bioservices has a consensus price target of --, signalling upside risk potential of 5.02%. On the other hand Catalent has an analysts' consensus of $63.50 which suggests that it could fall by -0.08%. Given that Avid Bioservices has higher upside potential than Catalent, analysts believe Avid Bioservices is more attractive than Catalent.

Avid Bioservices has a beta of 1.444, which suggesting that the stock is 44.417% more volatile than S&P 500. In comparison Catalent has a beta of 1.146, suggesting its more volatile than the S&P 500 by 14.582%.

Avid Bioservices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalent offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avid Bioservices pays -- of its earnings as a dividend. Catalent pays out -- of its earnings as a dividend.

Avid Bioservices quarterly revenues are $33.5M, which are smaller than Catalent quarterly revenues of $1B. Avid Bioservices's net income of -$17.4M is higher than Catalent's net income of -$129M. Notably, Avid Bioservices's price-to-earnings ratio is -- while Catalent's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avid Bioservices is 5.18x versus 2.61x for Catalent. Usually stocks with elevated PS ratios are considered overvalued.

iBio has a net margin of -51.99% compared to Avid Bioservices's net margin of -4444.57%. Avid Bioservices's return on equity of -143.94% beat iBio's return on equity of -148.3%.

Avid Bioservices has a consensus price target of --, signalling upside risk potential of 5.02%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 49.05%. Given that iBio has higher upside potential than Avid Bioservices, analysts believe iBio is more attractive than Avid Bioservices.

Avid Bioservices has a beta of 1.444, which suggesting that the stock is 44.417% more volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

Avid Bioservices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avid Bioservices pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Avid Bioservices quarterly revenues are $33.5M, which are larger than iBio quarterly revenues of $175K. Avid Bioservices's net income of -$17.4M is lower than iBio's net income of -$4M. Notably, Avid Bioservices's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avid Bioservices is 5.18x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -51.99% compared to Avid Bioservices's net margin of -49.65%. Avid Bioservices's return on equity of -143.94% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Avid Bioservices has a consensus price target of --, signalling upside risk potential of 5.02%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 589.94%. Given that NovaBay Pharmaceuticals has higher upside potential than Avid Bioservices, analysts believe NovaBay Pharmaceuticals is more attractive than Avid Bioservices.

Avid Bioservices has a beta of 1.444, which suggesting that the stock is 44.417% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Avid Bioservices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avid Bioservices pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Avid Bioservices quarterly revenues are $33.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Avid Bioservices's net income of -$17.4M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Avid Bioservices's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avid Bioservices is 5.18x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -51.99% compared to Avid Bioservices's net margin of -2357.27%. Avid Bioservices's return on equity of -143.94% beat Palatin Technologies's return on equity of --.

Avid Bioservices has a consensus price target of --, signalling upside risk potential of 5.02%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1617.17%. Given that Palatin Technologies has higher upside potential than Avid Bioservices, analysts believe Palatin Technologies is more attractive than Avid Bioservices.

Avid Bioservices has a beta of 1.444, which suggesting that the stock is 44.417% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Avid Bioservices has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avid Bioservices pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Avid Bioservices quarterly revenues are $33.5M, which are larger than Palatin Technologies quarterly revenues of $350K. Avid Bioservices's net income of -$17.4M is lower than Palatin Technologies's net income of -$7.8M. Notably, Avid Bioservices's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avid Bioservices is 5.18x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.